Therapies targeting B7-H3 and PD-1/PD-L1 axis may have a beneficial effect on this malignancy, since they may counteract the immunosuppression induced by B7-H3 and the PD-1 axis and may inhibit the metastatic potential of chondrosarcoma cells. Here, CD276 is linked to chondrosarcoma.